(UroToday.com) Dr. Payal Kapur kicked off the session “Managing Renal Cell Carcinoma at All Stages From Research to Practice” with an excellent talk reviewing the ever-changing pathologic classification of renal cell carcinoma.
(UroToday.com) Dr. Hoffman-Censits concluded the session by presenting on the topic of sequencing systemic therapies and looking to the future in the management of metastatic urothelial carcinoma.
(UroToday.com)Dr. Baumann presented on the role of Radiation Therapy in Oligometastatic and Locally Recurrent Urothelial Carcinoma, as part of this session on Multidisciplinary Care in Early- and Late-Stage Urothelial Cancer.
(UroToday.com) The 2023 American Society of Clinical Oncology Genitourinary (ASCO GU) cancers symposium held in San Francisco, CA between February 16th and 18th was host to a Multidisciplinary Perspectives on Challenging Renal Cell Carcinoma Cases session. Dr. Fabien Moinard-Butot presented the results of his group’s study evaluating the effect of treatment of residual disease after immunotherapy-based combinations on complete response rate in metastatic renal cell carcinoma.
(UroToday.com) The 2023 American Society of Clinical Oncology Genitourinary (ASCO GU) cancers symposium held in San Francisco, CA between February 16th and 18th was host to a prostate cancer poster session. Dr. Sean Collins presented the results of his group’s study identifying prostate cancer patient subgroups based on their preferences for key attributes of androgen deprivation therapy (ADT).
(UroToday.com) The need for additional effective therapies for metastatic castration resistant prostate cancer (mCRPC) is omnipresent, particularly as therapies previously used in later lines or only in CRPC are now being deployed in earlier disease states. Among well-established mechanisms of resistance are alterations in the androgen receptor (AR), including mutations and copy number changes, which effect its activity and ligand independent signaling. EPI-7386 is an aniten, a class of compounds which can inhibitor AR activity by binding to the N-terminal domain (NTD) irrespective of resistance abrogation in the ligand binding domain that may otherwise make AR signaling inhibitors ineffective, as supported by preclinical data. Trial of this agent in a first-in-human study in heavily pre-treated patients with mCRPC was undertaken (NCT04221222), and preliminary data are reported here.
Reno, Nevada (UroToday.com) -- Photocure ASA, The Bladder Cancer Company, announces the presentation of clinical data from the Veterans Affairs (VA) BRAVO study at the ASCO Genitourinary Cancers Symposium (ASCO GU) which was held February 16-18, 2023 in San Francisco, USA. The clinical data demonstrated a significant decrease in the risk of recurrence & longer time to recurrence following Blue Light cystoscopy (BLC®) with Cysview® compared to White Light cystoscopy (WLC) alone.
(UroToday.com) The 2023 GU ASCO annual meeting included an oral abstract session on renal cell carcinoma (RCC), featuring a presentation by Dr. Mauricio Burotto discussing 3-year follow-up from the phase 3 CheckMate 9ER trial assessing nivolumab plus cabozantinib vs sunitinib for first-line treatment of advanced RCC. First-line nivolumab plus cabozantinib demonstrated superiority over sunitinib with 25.4 months minimum follow-up (median, 32.9 months) in patients with advanced RCC in the CheckMate 9ER trial.1 At the 2023 GU ASCO annual meeting, Dr. Burotto and colleagues reported survival, response per blinded independent central review, and safety after 3 year minimum follow-up in all randomized patients and by IMDC risk score.
(UroToday.com) The 2023 GU ASCO annual meeting included an oral abstract session on renal cell carcinoma (RCC), featuring a presentation by Dr. Brian Shuch discussing results from ZIRCON, a phase 3 study of 89Zr-DFO-girentuximab for PET/CT imaging of clear cell RCC. The increasing detection of renal masses presents a significant patient management challenge. Diagnostic options include cross-sectional imaging, which cannot reliably differentiate benign and malignant renal masses, and biopsy, which is invasive and subject to sampling errors. Furthermore, 20-30% of resected small renal masses are benign, and clear cell RCC is 75% of RCC and causes ~90% of deaths. These limitations highlight the unmet need for accurate noninvasive method for pre-treatment risk stratification, similar to the recent advancements in PSMA imaging in prostate cancer. Girentuximab is a monoclonal antibody that targets carbonic anhydrase IX, an enzyme highly expressed in clear cell renal carcinoma. Radiolabeled 89Zr-DFO-girentuximab (TLX250-CDx) is highly specific for carbonic anhydrase IX and can aid differentiation between clear cell RCCs and other renal lesions:
(UroToday.com) The 2023 American Society of Clinical Oncology Genitourinary (ASCO GU) cancers symposium held in San Francisco, CA between February 16th and 18th was host to a Renal Cell Cancer; Adrenal, Penile, Urethral, and Testicular Cancers poster session. Sandra Alonso Paz presented the results of her group’s study evaluating deep learning techniques in RNA sequencing data for the prediction of response to immune checkpoint inhibitors in patients with metastatic RCC.
(UroToday.com) The 2023 American Society of Clinical Oncology Genitourinary (ASCO GU) cancers symposium held in San Francisco, CA between February 16th and 18th was host to a Renal Cell Cancer; Adrenal, Penile, Urethral and Testicular Cancers poster session. Dr. Yann-Alexandre Vano presented the overall survival and second-line treatment efficacy in metastatic clear cell renal cell carcinoma patients treated in the randomized phase II BIONIKK trial.
(UroToday.com) The 2023 American Society of Clinical Oncology Genitourinary (ASCO GU) cancers symposium held in San Francisco, CA between February 16th and 18th was host to a Renal Cell Cancer; Adrenal, Penile, Urethral and Testicular Cancers poster session. Dr. Jing Liu presented the results of a phase II trial of combination PD-1 immune checkpoint inhibition with all-lesion stereotactic radiation (SBRT) in oligometastatic renal cell carcinoma (RCC).
(UroToday.com) The 2023 American Society of Clinical Oncology Genitourinary (ASCO GU) cancers symposium held in San Francisco, CA between February 16th and 18th was host to a Renal Cell Cancer; Adrenal, Penile, Urethral and Testicular Cancers poster session. Dr. Michael Atkins presented the treatment-free survival (TFS) outcomes of Cohort A from HCRN GU16-260, a phase II trial of nivolumab and salvage nivolumab + ipilimumab in advanced clear cell RCC.
(UroToday.com) The 2023 American Society of Clinical Oncology Genitourinary (ASCO GU) cancers symposium held in San Francisco, CA between February 16th and 18th was host to a Renal Cell Cancer; Adrenal, Penile, Urethral and Testicular Cancers poster session. Dr. Toni Choueiri presented subgroup analysis of the KEYNOTE-564 trial of adjuvant pembrolizumab for renal cell carcinoma across the UCLA Integrated Staging System (UISS) risk groups and disease stage.
(UroToday.com) The 2023 GU ASCO annual meeting included a session on biomarkers of response and risk stratification in genitourinary cancers, featuring a presentation by Dr. Robert Hamilton discussing work from the European Association of Urology Testicular Cancer Guidelines Panel, specifically a new prognostic factor risk group classification for patients with clinical stage 1 seminoma in active surveillance. Indeed, between 4%- 30% of patients with clinical stage 1 seminoma testis in active surveillance relapse depending on pathological risk factors, such as tumor size (>4 cm) and rete testis invasion.1 The level of evidence supporting these pathological risk factors in clinical decision-making is low due to heterogeneous study design and reporting, as well as difficulty analyzing patient subgroups according to combination of these factors. The objectives of the present study were to identify the most important pathological prognostic factors predicting relapse in clinical stage 1 seminoma patients with normal post-orchidectomy serum tumor marker levels in active surveillance and to construct risk groups for guiding treatment decision-making and follow-up.
(UroToday.com) In this rapid abstract, Dr. Talal El Zarif and colleagues report on the safety and efficacy of immune checkpoint inhibitors (ICIs) in advanced penile carcinoma (PeCa), based on their multinational cohort derived from the Global Society of Rare Genitourinary Tumors (GSRGT).
(UroToday.com) In this rapid abstract session, Dr. Michael Atkins presents on Treatment-Free Survival (TFS) outcomes from the Phase II study (HCRN GU16-260-Cohort A) of nivolumab and salvage nivolumab+ipilimumab in patients with advanced renal cell carcinoma (RCC).
(UroToday.com) In this study, Dr. Abdallah and colleagues evaluate the accuracy of fully automated, AI-generated models compared to validated clinical models to predict post-operative GFR after kidney surgery.
(UroToday.com)In this abstract, Lai and colleagues present on the impact of belzutifan (HIF2 inhibitor) on burden of surgery and surgical complications in patients with Von Hippel Lindau (VHL).
(UroToday.com) The 2023 GU ASCO annual meeting included a session on renal cell carcinoma (RCC), featuring a presentation by Dr. Yoshihiko Tomita discussing an exploratory analysis from JAVELIN Renal 101, specifically assessing C-reactive protein as a predictive marker for outcomes with avelumab + axitinib in patients with poor-risk advanced RCC. Analyses from the phase 3 JAVELIN Renal 101 trial1 (NCT02684006) suggested that CRP levels at baseline and early after treatment may predict outcomes with avelumab + axitinib in patients with advanced RCC. In addition, many patients with International Metastatic RCC Database Consortium (IMDC) poor risk who had prolonged progression-free survival (PFS) and overall survival (OS) were observed at the third interim analysis of OS. Dr. Tomita and colleagues analyzed the association between CRP levels and prolonged PFS/OS with avelumab + axitinib in patients with IMDC poor risk.
